Now that Britain has approved over-the-counter sales of anti-cholesterol statin drugs, the world's largest pharmaceutical companies are turning their sights to the U.S., where they already have begun lobbying for a similar decision. Johnson & Johnson-Merck Consumer Pharmaceuticals, a joint venture promoting FDA approval of OTC status for statins, is beginning its effort to get a low-dose version of its first statin drug, Mevacor, in the hands of people considered at 10% to 20% risk of having cholesterol problems.

Full Story:

Related Summaries